Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers

whitePaper | January 24, 2022

Since early 2020, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome.

whitePaper | February 11, 2022

The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.

whitePaper | December 15, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

whitePaper | January 31, 2023

The first biosimilar approved under the abbreviated pathway established by the Biologics Price Competition and Innovation Act launched in the U.S. in 2015.